Inovio Pharma (INO) – Analyst EPS Change
-
Inovio Pharmaceuticals (INO) Unlikely to be a COVID Vaccine Contender, Roth Capital Reiterates Sell
-
UPDATE: Inovio Pharmaceuticals (INO) PT Raised to $12 at Maxim Group; 'A Step Closer to HIV Vaccine, PENNVAX-GP Demonstrates High Immune Response Rates'
-
Back to INO Stock Lookup